Barclays initiated coverage of C4 Therapeutics (CCCC) with an Overweight rating and $8 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics: Promising Growth and Competitive Edge with TORPEDO Platform and Strategic Partnerships
- C4 Therapeutics upgraded to Overweight from Equal Weight at Stephens
- Brookline sees potential upside to outlook for C4 Therapeutics after Biogen news
- C4 Therapeutics announces Biogen had its IND for BIIB142 accepted by FDA
- C4 Therapeutics initiated with a Buy at Guggenheim